Becton, Dickinson and Company

WBAG:BDX Stock Report

Market Cap: €62.6b

Becton Dickinson Valuation

Is BDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BDX (€216.2) is trading below our estimate of fair value (€296.75)

Significantly Below Fair Value: BDX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BDX?

Key metric: As BDX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BDX. This is calculated by dividing BDX's market cap by their current earnings.
What is BDX's PE Ratio?
PE Ratio38.2x
EarningsUS$1.71b
Market CapUS$65.68b

Price to Earnings Ratio vs Peers

How does BDX's PE Ratio compare to its peers?

The above table shows the PE ratio for BDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.3x
SHL Siemens Healthineers
30.8x14.2%€59.9b
EW Edwards Lifesciences
27.6x3.3%US$43.6b
MDT Medtronic
24.7x10.2%US$106.1b
GEHC GE HealthCare Technologies
22.1x11.5%US$37.3b
BDX Becton Dickinson
38.2x14.2%€65.7b

Price-To-Earnings vs Peers: BDX is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the peer average (26.3x).


Price to Earnings Ratio vs Industry

How does BDX's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BDX 38.2xIndustry Avg. 29.9xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BDX is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the European Medical Equipment industry average (30.2x).


Price to Earnings Ratio vs Fair Ratio

What is BDX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BDX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BDX's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BDX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€216.20
€268.26
+24.1%
8.7%€312.93€234.07n/a16
Dec ’25€210.40
€268.16
+27.5%
8.5%€312.47€238.48n/a16
Nov ’25€217.90
€256.59
+17.8%
8.4%€296.24€218.76n/a16
Oct ’25€218.90
€253.69
+15.9%
8.6%€293.61€216.82n/a16
Sep ’25€217.50
€252.09
+15.9%
7.9%€296.14€218.69n/a16
Aug ’25€213.00
€256.64
+20.5%
7.9%€301.18€222.41n/a16
Jul ’25€216.50
€260.84
+20.5%
8.1%€303.65€224.23n/a16
Jun ’25€212.20
€257.34
+21.3%
8.1%€300.11€221.62n/a16
May ’25€218.50
€260.61
+19.3%
8.2%€303.62€224.21n/a14
Apr ’25€229.00
€259.62
+13.4%
7.6%€299.36€221.06n/a14
Mar ’25€216.50
€264.33
+22.1%
7.5%€303.49€224.11n/a15
Feb ’25€220.50
€262.63
+19.1%
7.4%€299.00€220.80n/a15
Jan ’25€220.00
€262.19
+19.2%
7.5%€299.98€221.52n/a15
Dec ’24€218.00
€267.30
+22.6%
7.7%€303.68€224.26€210.4015
Nov ’24€239.50
€286.53
+19.6%
5.2%€309.11€257.75€217.9015
Oct ’24€246.50
€283.36
+15.0%
5.2%€305.27€254.55€218.9015
Sep ’24€259.00
€277.00
+6.9%
5.3%€299.65€249.86€217.5016
Aug ’24€252.50
€263.91
+4.5%
6.5%€293.80€235.04€213.0016
Jul ’24€242.00
€267.35
+10.5%
4.8%€285.65€242.71€216.5015
Jun ’24€230.00
€259.25
+12.7%
4.9%€277.63€235.90€212.2015
May ’24€236.00
€254.55
+7.9%
6.8%€279.32€223.64€218.5015
Apr ’24€227.40
€256.09
+12.6%
6.7%€283.45€226.94€229.0013
Mar ’24€216.85
€256.09
+18.1%
6.7%€283.45€226.94€216.5013
Feb ’24€231.80
€250.65
+8.1%
6.6%€281.83€225.65€220.5013
Jan ’24€239.95
€252.11
+5.1%
6.5%€287.85€230.47€220.0013
Dec ’23€238.90
€256.62
+7.4%
8.1%€296.97€213.51€218.0012

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies